Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 871263, 9 pages
http://dx.doi.org/10.1155/2014/871263
Research Article

The Sirtuin 3 Expression Profile Is Associated with Pathological and Clinical Outcomes in Colon Cancer Patients

1Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China
2Department of General Surgery, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256600, China

Received 23 February 2014; Revised 28 April 2014; Accepted 29 May 2014; Published 1 July 2014

Academic Editor: Ferdinando Chiaradonna

Copyright © 2014 Chunyuan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Giovannucci, “Modifiable risk factors for colon cancer,” Gastroenterology Clinics of North America, vol. 31, no. 4, pp. 925–943, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Couzin, “Cancer. T cells a boon for colon cancer prognosis,” Science, vol. 313, no. 5795, pp. 1868–1869, 2006. View at Google Scholar · View at Scopus
  3. Y. François and J. Vignal, “Cancer of the colon. Etiology, physiopathology, diagnosis, development and prognosis, principles of the surgical treatment,” Revue du Praticien, vol. 41, no. 13, pp. 1221–1225, 1991. View at Google Scholar · View at Scopus
  4. B. C. Chiu, B. T. Ji, Q. Dai et al., “Dietary factors and risk of colon cancer in Shanghai, China,” Cancer Epidemiology, Biomarkers & Prevention, vol. 12, no. 3, pp. 201–208, 2003. View at Google Scholar · View at Scopus
  5. A. Barrier, P. Y. Boelle, F. Roser et al., “Stage II colon cancer prognosis prediction by tumor gene expression profiling,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4685–4691, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. H. Jee, S. M. Moon, U. S. Shin, H. M. Yang, and D. Hwang, “Effectiveness of adjuvant chemotherapy with 5-FU/ leucovorin and prognosis in stage II colon cancer,” Journal of the Korean Society of Coloproctology, vol. 27, no. 6, pp. 322–328, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Dotan and S. J. Cohen, “Challenges in the management of stage II colon cancer,” Seminars in Oncology, vol. 38, no. 4, pp. 511–520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Biffi, E. Botteri, E. Bertani et al., “Factors predicting worse prognosis in patients affected by pT3 N0 colon cancer: long-term results of a monocentric series of 137 radically resected patients in a 5-year period,” International Journal of Colorectal Disease, vol. 28, no. 2, pp. 207–215, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Kouraklis, S. Theocharis, P. Vamvakas et al., “Cyclin D1 and Rb protein expression and their correlation with prognosis in patients with colon cancer,” World Journal of Surgical Oncology, vol. 4, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Catalano, F. Loupakis, F. Graziano et al., “Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer,” Annals of Oncology, vol. 23, no. 1, pp. 135–141, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. A. Sauve, C. Wolberger, V. L. Schramm, and J. D. Boeke, “The biochemistry of sirtuins,” Annual Review of Biochemistry, vol. 75, pp. 435–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Li, H. Zeng, X. Hou, X. He, and J. X. Chen, “Myocardial injection of apelin-overexpressing bone marrow cells improves cardiac repair via upregulation of Sirt3 after myocardial infarction,” PLoS ONE, vol. 8, Article ID e71041, 2013. View at Publisher · View at Google Scholar
  13. S. Li, M. Banck, S. Mujtaba, M. Zhou, M. M. Sugrue, and M. J. Walsh, “p53-Induced growth arrest is regulated by the Mitochondrial SirT3 deacetylase,” PLoS ONE, vol. 5, no. 5, Article ID e10486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Y. Alhazzazi, P. Kamarajan, N. Joo et al., “Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer,” Cancer, vol. 117, no. 8, pp. 1670–1678, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Ashraf, S. Zino, A. MacIntyre et al., “Altered sirtuin expression is associated with node-positive breast cancer,” British Journal of Cancer, vol. 95, no. 8, pp. 1056–1061, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Zhang and L. Zhou, “Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation,” Biochemical and Biophysical Research Communications, vol. 423, no. 1, pp. 26–31, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Kim, K. Patel, K. Muldoon-Jacobs et al., “SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress,” Cancer Cell, vol. 17, no. 1, pp. 41–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. H. B. Burke and D. E. Henson, “The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system,” Cancer, vol. 72, no. 10, pp. 3131–3135, 1993. View at Publisher · View at Google Scholar
  19. Y. Yilmaz, O. Ozturk, Y. O. Alahdab et al., “Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease,” Digestive and Liver Disease, vol. 45, no. 1, pp. 58–62, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Liu, A. Sun, C. Wang, and L. Chen, “Expression of BRG1 and BRM proteins in prostatic cancer,” Chinese Journal of Pathology, vol. 39, no. 9, pp. 591–594, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. J. H. Lee, J. Pyon, S. H. Lee et al., “Greater expression of TC21/R-ras2 in highly aggressive malignant skin cancer,” International Journal of Dermatology, vol. 50, no. 8, pp. 956–960, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Li, M. Banck, S. Mujtaba, M. Zhou, M. M. Sugrue, and M. J. Walsh, “p53-Induced growth arrest is regulated by the Mitochondrial SirT3 deacetylase,” PLoS ONE, vol. 5, no. 5, Article ID e10486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. N. R. Sundaresan, S. A. Samant, V. B. Pillai, S. B. Rajamohan, and M. P. Gupta, “SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70,” Molecular and Cellular Biology, vol. 28, no. 20, pp. 6384–6401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Hundt, U. Haug, and H. Brenner, “Blood markers for early detection of colorectal cancer: a systematic review,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 10, pp. 1935–1953, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Onyango, I. Celic, J. M. McCaffery, J. D. Boeke, and A. P. Feinberg, “SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13653–13658, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. S. C. Dryden, F. A. Nahhas, J. E. Nowak, A. Goustin, and M. A. Tainsky, “Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle,” Molecular and Cellular Biology, vol. 23, no. 9, pp. 3173–3185, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. H.-S. Kim, K. Patel, K. Muldoon-Jacobs et al., “SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress,” Cancer Cell, vol. 17, no. 1, pp. 41–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Luo, C. Stock, B. Burwinkel, and H. Brenner, “Identification and evaluation of plasma microRNAs for early detection of colorectal cancer,” PLoS ONE, vol. 8, no. 5, Article ID e62880, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Huang, M. Li, C. Chen, and Q. Yao, “Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications,” Expert Opinion on Therapeutic Targets, vol. 12, no. 5, pp. 637–645, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Gavrilov and W. M. Saltzman, “Therapeutic siRNA: principles, challenges, and strategies,” Yale Journal of Biology and Medicine, vol. 85, no. 2, pp. 187–200, 2012. View at Google Scholar · View at Scopus
  31. S. I. Wang, H. H. Yao, and Z. H. Qin, “Strategies for short hairpin RNA delivery in cancer gene therapy,” Expert Opinion on Biological Therapy, vol. 9, no. 11, pp. 1357–1368, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Yang, X. Fu, L. Shao, Y. Ding, and D. Zeng, “Aberrant expression of SIRT3 is conversely correlated with the progression and prognosis of human gastric cancer,” Biochemical and Biophysical Research Communications, vol. 443, pp. 156–160, 2014. View at Publisher · View at Google Scholar
  33. H. R. Hagland, M. Berg, I. W. Jolma, A. Carlsen, and K. Søreide, “Molecular pathways and cellular metabolism in colorectal cancer,” Digestive Surgery, vol. 30, no. 1, pp. 12–25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. L. M. Butler, R. Wang, W.-. Koh, and M. C. Yu, “Prospective study of dietary patterns and colorectal cancer among Singapore Chinese,” British Journal of Cancer, vol. 99, no. 9, pp. 1511–1516, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. A. O. Odegaard, W.-P. Koh, and J.-M. Yuan, “Combined lifestyle factors and risk of incident colorectal cancer in a Chinese population,” Cancer Prevention Research, vol. 6, no. 4, pp. 360–367, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Xu, X. Hou, N. Wang et al., “Gender-specific effect of estrogen receptor-1 gene polymorphisms in coronary artery disease and its angiographic severity in Chinese population,” Clinica Chimica Acta, vol. 395, no. 1-2, pp. 130–133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. X. W. Hou, R. Q. Yang, Y. G. Zhong, W. Gao, S. P. Sun, and N. F. Wang, “G501C polymorphism of the oxidized LDL receptor gene is associated with albuminuria in Chinese essential hypertension patients,” Genetics and Molecular Research, vol. 10, no. 4, 2011. View at Google Scholar · View at Scopus
  38. S. Zhang, X. Hou, S. Zi, Y. Wang, L. Chen, and B. Kong, “Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients,” Cellular Physiology and Biochemistry, vol. 31, no. 4-5, pp. 525–531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. J. M. Carethers, “Proteomics, genomics, and molecular biology in the personalized treatment of colorectal cancer,” Journal of Gastrointestinal Surgery, vol. 16, no. 9, pp. 1648–1650, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. C. M. Ribic, D. J. Sargent, M. J. Moore et al., “Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer,” The New England Journal of Medicine, vol. 349, no. 3, pp. 247–257, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. X. W. Hou, J. Son, Y. Wang et al., “Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats,” Cardiovascular Drugs and Therapy, vol. 20, no. 2, pp. 85–91, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Boyle, J. Heyworth, F. Bull, S. McKerracher, C. Platell, and L. Fritschi, “Timing and intensity of recreational physical activity and the risk of subsite-specific colorectal cancer,” Cancer Causes and Control, vol. 22, no. 12, pp. 1647–1658, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. R. J. DeBerardinis, J. J. Lum, G. Hatzivassiliou, and C. B. Thompson, “The biology of cancer: metabolic reprogramming fuels cell growth and proliferation,” Cell Metabolism, vol. 7, no. 1, pp. 11–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Hou, S. Wang, Y. Zhou et al., “Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population,” International Journal of Hematology, vol. 82, no. 3, pp. 206–209, 2005. View at Publisher · View at Google Scholar · View at Scopus